Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03370822
Other study ID # 201920
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 22, 2016
Est. completion date December 31, 2017

Study information

Verified date May 2018
Source University of Manchester
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A stillbirth describes when a baby dies after 24 weeks of pregnancy and before being born. In the UK there are roughly 9 stillbirths every day. Normally, before a stillbirth occurs changes such as a slower heart rate and reduced movement take place. Fetal monitoring attempts to detect these changes so that babies can be delivered before they become severely ill. If a baby could be monitored continuously then these changes could be detected earlier. However, current forms of fetal monitoring, such as ultrasound, cannot be used for long periods of time and do not significantly reduce stillbirth rates. The Monica AN24 device is a continuous monitor which records the baby's heart rhythm using sensors placed on the mother's abdomen. As this is a new device there is little evidence about how well it works. In this project women will be asked how they feel about the device after wearing it. Doctors and midwives will also be asked about their views of the device. The effect of the mother's movement and the age of the baby on how well the Monica AN24 can record the baby's heart rhythm will also be assessed.


Description:

In the United Kingdom (UK) stillbirth is defined as the death of a fetus before birth and after 24 weeks gestation. The incidence of stillbirth in the UK was 4.6 per 1000 in 2014. The annual rate of reduction was 1.4%, a rate considerably lower than other high income countries, such as Poland (4.5%) and Netherlands (6.8%), demonstrating that more can be done to reduce stillbirth rates in the UK. Stillbirths are often preceded by a series of adaptive changes, including changes in fetal heart rate (FHR) and reduced fetal movement. Fetal monitoring serves, in part, to identify these changes so that appropriate intervention can be initiated and adverse outcomes prevented. However, currently used forms of fetal monitoring, including Doppler ultrasound and cardiotocography, cannot provide an objective, longitudinal view of fetal wellbeing and do not significantly reduce stillbirth rates. A continuous fetal monitor could identify signs of fetal compromise earlier.

A recent study found that 45.1% of surveyed clinicians thought that a continuous fetal monitor would be beneficial to their practice, although 81.7% also expressed concerns about the utility and clinical implementation of such a device. The Monica AN24 monitor is a novel continuous fetal monitoring device which records the fetal electrocardiogram (fECG) via trans-abdominal electrodes. Monica AN24 has been shown to have good recording quality though one study reported an association between recording quality and gestational age. The effect of the device on maternal anxiety is not known. All studies assessing acceptability of the device to women have focused on the intrapartum period or during induction of labor. Consequently, a prospective observational cohort study is needed to assess the acceptability of the Monica AN24 device in the context of antenatal care, as is further exploration of factors affecting recording quality of the Monica AN24 device.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 31, 2017
Est. primary completion date July 31, 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Women with singleton pregnancies attending St. Mary's Hospital, Manchester for antenatal care

- No abnormality identified on ultrasound scan of fetal biometry and umbilical and fetal Doppler indices

- Gestational age >24 weeks

- Able to give informed consent

Exclusion Criteria:

- Multiple pregnancies

- Maternal age <18 years

- Individuals who do cannot speak or do not understand fluent English

- Individuals unable to give informed consent

- Women in active labour

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MONICA AN24 device
Application of MONICA AN24 device and recording for the longest period of fetal heart rate recording possible (limited by battery life)

Locations

Country Name City State
United Kingdom Central Manchester University Hospitals NHS Foundation Trust Manchester

Sponsors (1)

Lead Sponsor Collaborator
University of Manchester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mother's experience of wearing device Qualitative Interview conducted within 24 hours of wearing the AN24 device Immediately following the period (usually 12-24 hours) of wearing MONICA AN24 device
Primary Change in Maternal Anxiety (GAD-2) Change in maternal anxiety as assessed by Generalised Anxiety Disorder 2 item (GAD-2) Maternal completion of the GAD-2 questionnaire before wearing the MONICA AN24 device and immediately following the period of wearing the MONICA AN24 device.
Primary Change in Maternal Anxiety (Pregnancy Specific Anxiety Score) Change in maternal anxiety as assessed by Pregnancy Specific Anxiety Score Maternal completion of the Pregnancy Specific Anxiety Score questionnaire before wearing the MONICA AN24 device and immediately following the period of wearing the MONICA AN24 device.
Primary Maternal Anxiety (STAI) Change in maternal anxiety as assessed by State Trait Anxiety Index. Maternal completion of the STAI before wearing the MONICA AN24 device and immediately following the period of wearing the MONICA AN24 device.
Secondary Recording quality - defined as the percentage of time the device recorded the fetal heart rate The recording quality of the Monica AN24 device defined as the percentage of time the device recorded the fetal heart rate) with differing levels of maternal activity and differing gestational ages. During the 12-24 hour recording period
See also
  Status Clinical Trial Phase
Completed NCT02221440 - Maternal Oxygen Administration for Fetal Distress N/A
Completed NCT04325243 - Sildenafil Citrate and Intrapartum Fetal Distress Phase 4
Completed NCT03095937 - Evaluation of Fetal Cardiac Function in Rheumatic Heart Disease (RHD) Patients
Completed NCT00185887 - Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation N/A
Completed NCT02862925 - Introducing Fetal Scalp Stimulation as an Adjunct to Intermittent Auscultation in Low-Resource Settings. N/A
Recruiting NCT06186973 - Fetal Assessment of the Myocardium and Evaluation of the Neonate
Recruiting NCT05681624 - Maternal Oxygen Supplementation for Intrauterine Resuscitation N/A
Recruiting NCT05946681 - Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings
Completed NCT03536910 - Evaluation of Copeptin Levels in Elective Cesarean Section With Different Anesthetic Technique N/A
Completed NCT03156608 - Novii External Fetal Monitoring Device N/A
Recruiting NCT00246766 - Study of Fetal Movements Using Multichannel Ultrasound Pulsed Doppler in Normal and Pathologic Pregnancy N/A
Recruiting NCT04043299 - Effect of Intrapartum Oxygen Administration on Fetal and Early Neonatal Outcomes Phase 3
Not yet recruiting NCT03859037 - Effect of Umbilical Cord Milking on Transition of Preterm Babies During Resuscitation N/A
Terminated NCT05147584 - Trans-abdominal Fetal Pulse Oximetry N/A
Not yet recruiting NCT05727241 - Three-dimensional Umbilical Cord Coiling Index
Terminated NCT04081584 - Trans-abdominal Fetal Pulse Oximetry: Tissue Light Scattering
Completed NCT03764696 - Maternal Oxygen Administration for Fetal Distress II N/A
Completed NCT01042262 - Maternal Oxygen Use During Delivery and Cord Blood Superoxide Dismutase N/A
Not yet recruiting NCT04548453 - Establish the uSI Values and End-user Training Material That Will be Used to Guide Oxytocin Dosing Actions Early Phase 1
Completed NCT03159234 - Prediction of Fetal Lung Maturity N/A